Using beta-blockers for heart attack patients in intensive care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of the beta-blocker metoprolol on patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who are classified as SCAI B upon admission to the cardiac intensive care unit. Patients will be randomly assigned to receive either metoprolol or a placebo for a duration of 72 hours, with continuous monitoring of vital signs and lactate levels. The primary goal is to determine if metoprolol can improve patient outcomes or prevent deterioration in their condition. Safety is prioritized, allowing for the study to be halted if necessary.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.
* Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \>0.5 mL/kg/hour).
* Age 18 years or older.
* Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.

Exclusion Criteria:

* Pregnancy.
* Inability to provide informed consent.
* Evidence of pulmonary edema.
* Bradycardia (heart rate \<60 beats per minute).
* PR interval \>240 milliseconds.
* Second- or third-degree atrioventricular (AV) block.
* Active asthma.
* Known hypersensitivity to metoprolol.

Where it's running

• Tel Aviv Sourasky Medical center
  Tel Aviv, Israel Recruiting

Study contacts

• Principal investigator: Yishay Szekely, MD — Tel-Aviv Sourasky Medical Center
• Study coordinator: Shir Frydman, MD
• Email: shirfrydman@gmail.com
• Phone: 0544267898

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivabradine for cardiogenic shock after a heart attack

  A study tests whether taking ivabradine can help people with cardiogenic shock after a heart attack move down at least one class on the SCAI scale and need less time on blood pressure or heart-support medicines.

  Recruiting Phase 3 National Institute of Cardiovascular Diseases, Pakistan · Karachi · NCT07714746

• Rapid escalation from Impella CP to Impella 5.5 in cardiogenic shock after myocardial infarction

  This observational study tests whether quickly upgrading from an Impella CP to an Impella 5.5 in patients with heart failure after a heart attack improves outcomes.

  Recruiting at 3 sites University Hospital of Cologne · Düsseldorf, North Rhine-Westphalia and 2 other locations · NCT07655479

• Optimizing Impella 5.5 Outcomes With Advanced Data Science

  This study tests whether real-world data from Impella 5.5 patients with cardiogenic shock can help predict heart recovery and prevent complications, using advanced data science.

  Recruiting Medical University of Vienna · Vienna · NCT07619144

• Cardiogenic Shock Outcomes Registry (COR-SHOCK): how patients fare over time

  This observational registry tests how outcomes and management of cardiogenic shock have changed over the years in adults receiving routine care.

  Recruiting Hospital de Santa Cruz, Portugal · Carnaxide, Lisbon District · NCT07597291

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Outcomes in patients with mixed cardiogenic and vasoplegic shock

  This registry will try to describe outcomes and risk factors in adults admitted with cardiogenic shock who also have inappropriate vasodilation (mixed cardiogenic‑vasoplegic shock).

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Somme · NCT07354568

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.